Neuroptika announces enrollment of first patient in phase 2 clinical trial for dry eye disease

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jan 17, 2020 at 12:32 PM.

  1. #1 cafead, Jan 17, 2020 at 12:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,024
    Likes Received:
    3
    via Neuroptika, a privately held biotechnology company focused on the development of novel regenerative treatments for ophthalmic diseases, announced that the first patient was enrolled in a Phase 2 clinical trial of NRO-1 for the treatment of dry eye disease.

    article source
     
    Quote

Reply to Thread